NCT06922825 2026-01-21
Pilot Study Evaluating Tumor Microenvironment Interaction in Solid Tumor Patients
Vanderbilt-Ingram Cancer Center
Phase EARLY_PHASE1 Withdrawn
Clinical Trials
14 trialsNCT06967987 2026-01-21
BEMAFLOT
Institut Cancerologie de l'Ouest
Phase 2 Withdrawn
NCT07293520 2025-12-26
Improving Consent Experiences in Clinical Trials
Washington University School of Medicine
Phase NA Withdrawn
NCT04020029 2025-12-19
Leveraging Mindsets to Improve Health and Wellbeing in Patients With Cancer
Stanford University
Phase NA Withdrawn
NCT04372641 2025-09-17
Testing the Safety of CB-5339 in Patients With Cancer
National Cancer Institute (NCI)
Phase 1 Withdrawn
NCT06762808 2025-08-15
Phase II Study of Atezolizumab and Tiragolumab With ctDNA for HPV-positive SCC
M.D. Anderson Cancer Center
Phase 2 Withdrawn
NCT05052632 2025-08-13
Evaluating a New Gonadotoxic Risk Stratification System
University of Colorado, Denver
Withdrawn
NCT05000905 2025-08-06
Improving Cognition and Behavior in Pediatric Cancer Survivors Using a Novel Mindful Attention Training
University of California, San Francisco
Phase NA Withdrawn
NCT06161558 2025-07-16
Erlotinib in Combination With Select Tyrosine Kinase Inhibitors in Adult Patients With Advanced Solid Tumors
National Institutes of Health Clinical Center (CC)
Phase 1 Withdrawn
NCT05257707 2025-07-09
MOCA
Centre Hospitalier Universitaire de Besancon
Phase NA Withdrawn
NCT06416436 2025-06-29
Dose-escalation Study of Ultra-high Dose Ablative Radiosurgery With Immunotherapy for Bulky Metastatic Cancer Patients
University of Kansas Medical Center
Phase 1 Withdrawn
NCT06390657 2025-05-11
S-C-PATHY
EBG MedAustron GmbH
Withdrawn
NCT06395090 2025-04-08
MK-9999-01B
Merck Sharp & Dohme LLC
Phase 1/2 Withdrawn
NCT05828303 2025-04-01
A Phase 1 Study to Evaluate the Potential Drug Interactions Between Repotrectinib and Metformin, Digoxin, and Rosuvastatin in Patients With Advanced Solid Tumors
Turning Point Therapeutics, Inc.
Phase 1 Withdrawn